Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer.
immunotherapy
lung cancer
prognostic biomarkers
splenomegaly
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Jun 2021
16 Jun 2021
Historique:
received:
06
05
2021
revised:
10
06
2021
accepted:
14
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Monoclonal antibodies targeting PD1/PD-L1 are game changers in advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosuppressive cells. The aim of this study was to evaluate the prognostic role of splenic volume in NSCLC patients treated with immune checkpoint inhibitors (ICIs). We conducted a retrospective study of 276 patients receiving ICIs for advanced NSCLC in the Georges François Leclerc Cancer Center. The association between splenic volume at baseline and at two months of therapy and progression-free survival (PFS) during ICI treatment or overall survival (OS) from ICI initiation was evaluated using univariate and multivariable Cox analyses. Splenic volume during treatment and the change in splenic volume were associated with poor PFS (respectively
Identifiants
pubmed: 34208673
pii: cancers13123020
doi: 10.3390/cancers13123020
pmc: PMC8234633
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2013;8(2):e57114
pubmed: 23437326
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Sci Rep. 2017 Apr 9;7(1):753
pubmed: 28392554
J Immunother Cancer. 2019 Sep 18;7(1):255
pubmed: 31533831
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33462141
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Ann Oncol. 2016 Apr;27(4):732-8
pubmed: 26802161
Cancer Res. 2016 Sep 15;76(18):5241-52
pubmed: 27496709
Immunity. 2013 Nov 14;39(5):806-18
pubmed: 24238338
Cancer Immunol Immunother. 2017 Jun;66(6):753-764
pubmed: 28283696
Oncotarget. 2018 May 22;9(39):25617-25629
pubmed: 29876012
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33495297
Clin Cancer Res. 2016 Nov 15;22(22):5487-5496
pubmed: 27185375
J Cell Mol Med. 2009 Sep;13(9B):3939-50
pubmed: 20196788
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
pubmed: 21644036
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Eur Radiol. 1997;7(2):246-8
pubmed: 9038125
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Hepatol Res. 2014 Jun;44(6):639-50
pubmed: 23701406
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Clin Chest Med. 2020 Mar;41(1):1-24
pubmed: 32008623
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Cancers (Basel). 2020 May 31;12(6):
pubmed: 32486421
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Oncotarget. 2017 Apr 11;8(15):24380-24388
pubmed: 28412745
Cancer Treat Rev. 2017 Jul;58:1-13
pubmed: 28602879
Cancer Immunol Immunother. 2017 Apr;66(4):503-513
pubmed: 28108766
J Immunol Res. 2014;2014:879897
pubmed: 24741628
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682